RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, will ring The Opening Bell® of the New York Stock Exchange (NYSE) on Wednesday, July 9, 2014. The company began trading as an NYSE MKT listed company on April 15, 2014.
“TransEnterix is proud to ring the opening bell on behalf of our entire team and investors to celebrate our recent listing to the New York Stock Exchange. Our listing represents an important step for the company to realize its vision of transforming robotic surgery for patients, surgeons and hospitals,” said Todd M. Pope, President and CEO of TransEnterix. “The NYSE is a fantastic platform for growth-stage medical device companies, and we look forward to a bright future on the exchange.”
Mr. Pope will be joined by several members of the management team and board of directors as he rings the opening bell at 9:30am EST on July 9, 2014. A live feed of the NYSE Opening Bell (9:26 a.m. ET) can be found at http://new.livestream.com/NYSE. Photos and video of the NYSE Bell Ringing Ceremony will also be available, courtesy of the NYSE, on Facebook (NYSE), Twitter (@NYSE and @NYSECam), and YouTube (nysetv1).
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery. The company is focused on the development and commercialization of the SurgiBot™ system, a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field. For more information, visit the company's website at www.transenterix.com.
Forward-Looking Statements
This press release includes statements relating to our SurgiBot system. These statements and other statements regarding our future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include but are not limited to: the pace of adoption of our product technology by surgeons, the success and market opportunity of our continuing and new product development efforts, including the SurgiBot system; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2013, as amended; and subsequent SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
